BioAlliance suspends doxorubicin Transdrug study

BioAlliance (Euronext:BIO) suspended a European Phase II/III trial of a 30 mg/m2 dose of doxorubicin Transdrug to treat hepatocellular carcinoma (HCC). The trial's DSMB and steering committee recommen...